18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

Inclusion Criteria:

1. Clinical diagnosed of neuroendocrine neoplasms.
2. Suspected of neuroendocrine neoplasms.

Exclusion Criteria:

1. Inability to undergo biopsy/surgical treatment.
2. Concurrent active malignancy.
3. Severe uncontrolled comorbidities/active infections.
4. Inability to provide informed consent.